SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical
company focused on developing engineered autologous T-cell therapy
(eACT™) products for the treatment of cancer, today announced that the
Company has entered into an exclusive, worldwide license with the
National Institutes of Health (NIH) for intellectual property related to
a fully human anti-CD19 chimeric antigen receptor-based product
candidate directed against B-cell malignancies. The National Cancer
Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator
in the Experimental Transplantation and Immunology Branch of the NCI, is
currently conducting a Phase 1 clinical trial of the product candidate
in patients with B-cell malignancies under an existing Cooperative
Research and Development Agreement (CRADA) between Kite and the NCI.
"The expansion of our CAR-T pipeline to include a fully human anti-CD19
chimeric antigen receptor supports our effort to maximize the potential
benefit of CAR-T therapies for patients with advanced B-cell
malignancies. As the field of T-cell therapy continues its rapid
advancement, we remain committed to collaborating with the world's most
distinguished institutions and accessing the most significant enabling
technologies to pioneer the next generation of T-cell therapies," said
Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance and the success of a fully human anti-CD19 chimeric antigen
receptor-based product candidate directed against B-cell malignancies
and the ability and willingness of the NCI to continue research and
development activities pursuant to the CRADA. Various factors may cause
differences between Kite's expectations and actual results as discussed
in greater detail in Kite's filings with the Securities and Exchange
Commission, including without limitation in its Form 10-Q filed with the
SEC on May 9, 2016. Any forward-looking statements that are made in this
press release speak only as of the date of this press release. Kite
assumes no obligation to update the forward-looking statements whether
as a result of new information, future events or otherwise, after the
date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160727006484/en/
Kite Pharma Contacts:
Source: Kite Pharma, Inc.
News Provided by Acquire Media